The radiologic images of 1–14-mm invasive breast carcinomas can be classified into 5 separate categories. The use of these mammographic indicators to predict patient outcome has important prognostic and therapeutic implications.
The radiologic images of 1–14-mm invasive breast carcinomas can be classified into 5 separate categories. The use of these mammographic indicators to predict patient outcome has important prognostic and therapeutic implications.
To verify the results of previous studies conducted with smaller numbers of patients, the authors studied the 24-year survival of 714 women with 1–14-mm invasive breast carcinoma according to mammographic prognostic factors. The association of mammographic features with lymph node status, histologic malignancy grade, and 24-year survival in 714 women with invasive breast carcinomas that measured 1–14 mm also was evaluated. Adjustments were made for tumor characteristics and treatment factors in the survival analysis.
The most common mammographic feature was a stellate lesion with no associated calcifications (420 women; 59%). Patients with stellate lesions had excellent long-term survival (95%). Casting-type calcifications were observed in 52 women (7%) and were associated significantly with a positive lymph node status (odds ratio [OR], 3.29; 95% confidence interval [95% CI], 1.41–7.67), poorer histologic grade (OR, 7.04; 95% CI, 3.77–13.16), and an increased risk of death from breast carcinoma (HR, 9.19; 95% CI, 4.18–20.17). Except for women who had tumors with associated casting-type calcifications, all other women with tumors < 10 mm in size had excellent survival regardless of lymph node status, histologic grade, or treatment. For women who had casting-type calcifications, survival was poorer even in the group with tumors that measured 1–9 mm (72% at 20 years). For women with 10–14-mm tumors, the 20-year survival rate was 52% for those who had casting calcifications and 86–100% those for those who had other mammographic features.
The subgroup of women who had small invasive breast carcinomas accompanied by casting-type calcifications had an unexpectedly poor prognosis for this tumor-size category. The process of neoductgenesis offers a possible explanation for the unexpectedly poor outcome. There is a need to develop treatment protocols for this group and to reevaluate the present TNM classification system for mammographically detected 1–14-mm breast carcinomas. After excluding women who had tumors associated with casting-type calcifications, the remaining women had an extremely good prognosis when they were treated with surgery alone. Due to their already excellent survival, adjuvant therapeutic regimens are unlikely to offer further benefit for these patients. Cancer 2004. © 2004 American Cancer Society.
The correlation between mammographic appearance and long-term prognosis in patients with small invasive breast carcinoma, particularly for those with T1a and T1b tumors, has gained importance as mammography service screening programs detect these small tumors in ever increasing numbers. Despite the excellent prognosis for the majority of patients with small breast carcinomas, a small number of women still die from T1a and T1b tumors after long-term follow-up. Previous studies have suggested that the mammographic features of these small tumors may be used to predict the long-term outcome of patients with breast carcinoma successfully. Three studies have found that the presence of casting-type microcalcifications on a mammogram is a reliable predictor for poor prognosis in women with small invasive breast carcinomas.1–3 One of those studies found a 20-year survival rate of only 55% for the subgroup of women who had 1–9-mm invasive breast carcinomas with associated casting-type calcifications, whereas the remaining women had a 95% 20-year survival rate.1 Similar findings were observed by Peacock et al.,2 Zunzunegui et al.,3 and Thurfjell et al.,4 although the latter study related to other types of calcifications in addition to the casting type. One study did not find an independent effect of the presence of casting-type calcifications on survival but noted a strong association of their appearance with poor histologic grade.5
Although the findings discussed above strongly support the association between mammographic appearance of invasive breast carcinomas and long-term outcome, the correlation between the so-called mammographic prognostic factors and histologic tumor attributes, such as lymph node status and histologic grade, remains unclear. Furthermore, the independent effect of mammographic features on long-term outcome after adjustment for tumor attributes and treatment modality also is uncertain in previous studies because of small sample sizes. To address these issues, a large study focusing on mammographic appearance and long-term prognosis for women with 1–14-mm invasive breast carcinomas would be required. Such a study must address the logistic problems of long-term follow-up in the group of women with T1a, T1b, and 10–14-mm invasive breast carcinomas, who generally have very good survival. It also must elucidate whether the correlation between mammographic appearance and regional lymph node spread or histologic grade allows mammographic appearance to be used as a surrogate endpoint for long-term outcome.
The objective of the current study was to examine the correlation between mammographic features and long-term outcome based on a large, consecutive cohort of women with 1–14-mm invasive breast carcinomas. The associations of mammographic appearance with regional lymph node spread and histologic grade were studied. The independent associations between mammographic appearance and long-term prognosis, adjusted for tumor attributes and treatment modality, also were assessed.
Overall, 715 consecutive patients ages 40–69 years with 1–14-mm invasive breast carcinoma were diagnosed in Dalarna County, Sweden, between October 3, 1977 and December 31, 1998 and were followed through December 31, 2001. Mammograms from the Swedish Two-County Trial and the subsequent service screening program6, 7 were available for review in all but one patient. Thus, the analysis was based on the remaining 714 patients. Of these, 247 patients had been included in our previous study.1 The tumors were categorized further according to size into 2 groups: 1–9 mm and 10–14 mm. Tumor size was based on a consensus between the radiologist, who measured the size of the invasive component on the specimen radiogram at the tumor board, and the judgment of the pathologist during histologic measurement, as well as on the large-section histology glass (10 cm × 8 cm). In the event of a discrepancy, the histologic tumor size was the final determinant.
The mammographic appearance of the invasive tumors in the current study was classified as 1) stellate without associated calcifications, 2) circular or oval-shaped mass without associated calcifications, 3) powdery calcifications with or without associated tumor mass on the mammogram, 4) casting-type calcifications with or without associated tumor mass, 5) crushed stone-like calcifications with or without associated tumor mass, and 6) others (e.g., galactographic findings, nonspecific asymmetric density). The major radiologic features are categorized readily (see Fig. 1).
The recorded histologic tumor characteristics included tumor size, histologic grade, (using the WHO grading system), and lymph node status. The choice of surgical treatment (breast-conserving surgery, mastectomy) and adjuvant treatment regimens (radiotherapy, chemotherapy, hormone therapy, or combinations of these) also were recorded. The outcome for each woman with breast carcinoma was determined as either death from breast carcinoma, death from other causes, or still alive at the end of follow-up.
The association between mammographic feature and lymph node status, with or without adjustment for histologic grade, patient age, and tumor size, was analyzed using a multiple logistic regression model. Unadjusted and adjusted odds ratios (ORs) and their 95% confidence intervals (95% CIs) associated with lymph node positivity were estimated using logistic regression. The ORs for histologic grade were estimated using proportional odds regression.8 To estimate the effect of mammographic appearance on long-term prognosis, the Cox proportional hazards model was used, adjusting for significant tumor attributes, such as lymph node status, histologic grade, or treatment modality.
Table 1 shows breast carcinoma deaths and numbers of patients by mammographic features and tumor size in the group of patients ages 40–69 years. Table 2 shows the distribution of mammographic features by tumor size in specific age groups: Women age < 50 years tended to have a greater proportion of masses with casting-type calcifications compared with women age > 50 years, although the difference was not statistically significant (P = 0.14). Circular or oval-shaped masses without associated calcifications were most common in the older women, whereas stellate masses without associated calcifications were distributed equally by age group. The younger women also were found to have greater proportions of powdery calcifications with or without an associated tumor mass. Overall, among tumors that measured 1–14 mm in greatest dimension, 59% were stellate without associated calcifications, 23% were circular or oval-shaped masses without associated calcifications, 3% had powdery calcifications with or without an associated tumor mass on the mammogram, 7% had crushed stone-like calcifications with or without mammographically demonstrable tumor mass, and 7% had casting-type calcifications. When they were subdivided further into tumor sizes 1–9 mm and 10–14 mm, the corresponding values were 51%, 22%, 6%, 9%, and 11% for tumors that measured 1–9 mm and 64%, 24%, 1%, 5%, and 5% for tumors that measured 10–14 mm, respectively.
|Mammographic appearance||Tumor size (mm)|
|Stellate without calcifications||1/154||12/266||13/420|
|Circular/oval without calcifications||2/66||8/101||10/167|
|Powdery calcifications ± without tumor mass||0/18||0/4||0/22|
|Crushed stone-like calcifications ± tumor mass||2/26||0/22||2/48|
|Casting-type calcifications ± tumor mass||6/32||9/20||15/52|
|Mammographic appearance||Tumor size (mm)|
|Women ages 40–49 yrs||Women ages 50–69 yrs|
|Stellate without calcifications||24||42.1||57||71.3||81||59.1||130||53.5||209||62.6||339||58.8|
|Circular/oval without calcifications||9||15.8||10||12.5||19||13.9||57||23.5||91||27.2||148||25.6|
|Powdery calcifications ± tumor mass||9||15.8||2||2.5||11||8.0||9||3.7||2||0.6||11||1.9|
|Crushed stone-like calcifications ± tumor mass||7||12.3||5||6.3||12||8.8||19||7.8||17||5.1||36||6.2|
|Casting-type calcifications ± tumor mass||8||14.0||6||7.5||14||10.2||24||9.9||14||4.2||38||6.6|
The correlations between mammographic appearance and regional lymph node spread and histologic grade are shown in Tables 3 and 4. Table 3 shows the ORs adjusted for age, histologic grade, and tumor size by inclusion of these factors in the logistic regression analysis. This was done to take account of any confounding by these factors. Similarly, in Table 4, estimates adjusted for age, lymph node status, and tumor size are shown. The OR for lymph node-positive disease with casting-type calcifications, relative to stellate lesions with no calcifications, was 3.29 (95% CI, 1.41–7.67) after adjusting for patient age, histologic grade, and tumor size. The corresponding values for circular or oval-shaped masses without associated calcification and for powdery calcifications or crushed stone-like calcifications with or without an associated tumor mass were 0.54 (95% CI, 0.26–1.11), 1.29 (95% CI, 0.22–7.54), and 1.00 (95% CI, 0.32–3.08), respectively. Table 4 shows the association between mammographic appearance and histologic grade. After controlling for patient age, lymph node status, and tumor size as a continuous variable, the proportional OR for patients with casting-type calcifications was found to be 7-fold (OR, 7.04; 95% CI, 3.77–13.16) and highly statistically significant (P < 0.001). It should be noted that this was due more to a preponderance of Grade 2 invasive tumors (66%) among patients who had casting-type calcifications rather than Grade 3 tumors (26%). Similar findings for casting-type calcifications were observed in separate subgroup analyses of the group with tumors that measured 1–9 mm in greatest dimension and the group with tumors that measured 10–14 mm in greatest dimension (data not shown).
|Mammographic appearance||Lymph node status||OR (95% CI)|
|Stellate without calcifications||323||45||1.00||1.00|
|Circular/oval without calcifications||132||12||0.65 (0.34–1.27)||0.54 (0.26–1.11)|
|Powdery calcifications ± tumor mass||15||2||0.96 (0.21–4.33)||1.29 (0.22–7.54)|
|Crushed stone-like calcifications ± tumor mass||42||4||0.68 (0.23–2.00)||1.00 (0.32–3.08)|
|Casting-type calcifications ± tumor mass||35||12||2.46 (1.19–5.09)||3.29 (1.41–7.67)|
|Mammographic appearance||Histologic tumor grade||OR (95% CI)|
|Stellate without calcifications||202||175||36||1.00||1.00|
|Circular/oval without calcifications||72||62||33||1.51 (1.07–2.12)||1.57 (1.11–2.23)|
|Powdery calcifications ± tumor mass||17||3||2||0.31 (0.12–0.83)||0.72 (0.26–2.01)|
|Crushed stone-like calcifications ± tumor mass||14||29||4||1.84 (1.03–3.29)||2.29 (1.25–4.21)|
|Casting-type calcifications ± tumor mass||4||33||13||5.41 (2.99–9.78)||7.04 (3.77–13.16)|
Tables 5 and 6 show surgical treatment modality and adjuvant therapy according to mammographic appearance. Prior to 1992, very little adjuvant therapy was used other than radiotherapy. Thus, for adjuvant therapy, data were available only for tumors that were diagnosed in the modern therapeutic era (1992–1998). Mastectomy was undergone by significantly greater proportions of women who had tumors with casting-type and crushed stone-like calcifications with or without an associated tumor mass on the mammogram, largely due to extensive ductal carcinoma in situ (DCIS), frequent occurrence of tumor at the resection margin, and additional foci found at histologic evaluation.
|Stellate without calcifications||134||31.9||281||66.9||5||1.2||420|
|Circular/oval without calcifications||49||29.3||117||70.1||1||0.6||167|
|Powdery calcifications ± tumor mass||5||22.7||17||77.3||0||0.0||22|
|Crushed stone-like calcifications ± tumor mass||29||60.4||19||39.6||0||0.0||48|
|Casting-type calcifications ± tumor mass||35||67.3||13||25.0||4||7.7||52|
|Mammographic appearance||RT only||CT only||T only||RT + CT||RT + T||RT + CT + T||None||Total|
|Stellate without calcifications||101||66.9||0||0.0||3||2.0||4||2.6||12||7.9||1||0.7||30||19.9||151|
|Circular/oval without calcifications||45||77.6||1||1.7||0||0.0||2||3.4||3||5.2||0||0.0||7||12.1||58|
|Powdery calcifications ± tumor mass||6||75.0||0||0.0||0||0.0||0||0.0||0||0.0||0||0.0||2||25.0||8|
|Crushed stone-like calcifications ± tumor mass||7||43.8||0||0.0||0||0.0||0||0.0||1||6.3||1||6.3||7||43.8||16|
|Casting-type calcifications ± tumor mass||8||53.3||1||6.7||0||0.0||1||6.7||2||13.3||0||0.0||3||20.0||15|
Table 1 shows the numbers of tumors and case fatalities by mammographic tumor characteristics and tumor-size categories. In the 1–14-mm size group, the women with casting-type calcifications were found to have the highest fatality rate (29%), followed by women with circular or oval-shaped masses without associated calcifications (6%), women with crushed stone-like calcifications with or without associated tumor mass (4%), and women with stellate lesions without associated calcifications (3%). The best outcome was observed in the group of women who had powdery calcifications with or without associated tumor mass (0% fatality).
Figure 2A–C shows cumulative survival by mammographic appearance. The common feature of these 24-year survival curves is the strikingly poor survival of women who had casting-type calcifications compared with the excellent survival of women in all of the other mammographically classified groups. Women with 1–9-mm invasive tumors associated with casting-type calcifications had a > 30-fold increased risk (relative risk [RR], 32.59; 95% CI, 3.92–270.88) of dying from breast carcinoma adjusted for tumor size compared with women who had stellate lesions with no calcifications. The corresponding RR estimates were 12.54 (95% CI, 5.27–29.88) for tumors that measured 10–14 mm and 11.35 (95% CI, 5.39–23.87) for tumors in the combined 1–14-mm size range. These differences in survival were highly statistically significant (P < 0.001 in all analyses).
Figure 3 shows cumulative survival associated with mammographic appearance of the tumors by lymph node status and tumor size. Among all lymph node-negative, 1–9-mm tumors, only women who had casting-type calcifications had a poor prognosis (76% survival), and women who had tumors with all other mammographic features had 87–100% 20–24-year survival. Even with increasing tumor size, there was no deterioration in outcome observed in the women who had lymph node-negative tumors without casting-type calcifications. Women who had casting-type calcifications were found to have a poor prognosis irrespective of their lymph node status or tumor size. Among women who had circular and stellate tumors with no associated calcifications, positive lymph node status started to affect outcomes when the tumors measured > 10 mm in greatest dimension. There were very few lymph node-positive tumors that measured 1–9 mm (10 of 300 tumors).
Figure 4 shows the effect of the mammographic tumor appearance on survival by histologic grade. The poorer prognosis for women who had tumors with casting-type calcifications was noted for Grade 2 and 3 tumors, but not Grade 1 tumors. However, there were relatively few women who had casting-type calcifications in low-grade tumors. It is interesting to note that the effect of mammographic features on survival was more apparent than the effect of grade. The survival of women who had circular/oval tumors without calcifications, although it was much better than the survival of women who had casting-type calcifications, was slightly poorer compared with the survival of women who had Grade 2 tumors in the other mammographic categories. Among the 10–14-mm Grade 3 tumors, the poorer survival of women who had casting-type calcifications was much more pronounced.
Figure 5 shows the cumulative survival curves for mammographic appearance by surgical treatment and radiotherapy. There was shorter follow-up for these patients due to the fact that we had information regarding treatment only for tumors that were diagnosed between 1992 and 1998. Those women who had tumors with associated casting-type calcifications were found to have poor survival regardless of the type of surgical treatment or postoperative radiotherapy, regardless of whether they received any adjuvant therapy. Women who had circular or oval-shaped masses without calcifications and had received radiotherapy or undergone breast-conserving surgery had intermediate survival rates. Women who had tumors in other categories were reported to have very good 24-year survival, regardless of the treatment modality chosen.
Table 7 shows the results of multiple proportional hazards regression of mammographic features of breast carcinoma and treatment adjusted for each other, with hazard ratios (HR) and 95% CIs. Tumors with casting-type calcifications still were associated with substantially poorer survival after adjustment for treatment factors. It should be noted that, because these are small tumors, few patients received any adjuvant treatment other than radiotherapy: hence the wide 95% CIs.
|None or others||1.00||—|
Table 8 shows the results of multiple Cox regression analysis for assessment of the impact of mammographic features of breast carcinomas on long-term prognosis after adjustment for lymph node status, histologic grade, and tumor size. To have sufficient deaths for estimation in each category, some categories with similar long-term outcome have been combined. After this adjustment, the risk of dying from breast carcinoma was found to be statistically significantly higher by a factor of 9 for women who had tumors associated with casting-type calcifications, compared with women who had stellate tumors without associated calcifications (RR, 9.19; 95% CI, 4.18–20.17). The only other mammographic category with an elevated risk of dying from breast carcinoma was the circular/oval tumors, but this did not quite reach statistical significance (RR, 1.88; 95% CI, 0.82–4.30). There were two nonsignificant but suggestive interactions in the Cox regression between tumor size and lymph node status and between tumor size and histologic grade. The poorer survival among women who had 10–14-mm tumors was confined to those with positive lymph node status and those with Grade ≥ 2 tumors.
|Lymph node status|
|Histologic tumor grade|
|Grade ≥ 2b||4.62||1.63–13.15|
|Stellate without calcifications||1.00||—|
|Circular/oval without calcifications||1.88||0.82–4.30|
The implications of the multivariate model can be seen more clearly in Table 9, which shows the fitted 20-year survival rates from the multivariate Cox model. Among women who had 1–9-mm tumors without casting-type calcifications, the 20-year fitted survival rate invariably was in excess of 90%, regardless of lymph node status or histologic grade. For women who had 1–9-mm, Grade 1 and Grade ≥ 2 tumors with casting-type calcifications, the survival rates were 83–84% and 65–67%, respectively. For women who had Grade 1, 10–14-mm tumors, the survival rate was > 90%, except for those who had casting-type calcifications (77–90%, depending on lymph node status). For women who had 10–14-mm, lymph node-negative, tumors of Grade ≥ 2, the survival rate was in excess of 80%, except for those who had casting-type calcifications (47% survival rate). For women who had 10–14-mm, lymph node-positive tumors, the survival rate was ≈ 80%, except for those who had circular/oval tumors with no calcifications (70%) and those who had casting-type calcifications, who had a very poor fitted survival rate of 18%.
|Lymph node status/mammographic appearance||Tumor size (mm)|
|Stellate, no calcifications||98||99|
|Circular/oval, no calcifications||97||97|
|Casting type calcifications||84||90|
|Grade ≥ 2|
|Stellate, no calcifications||96||92|
|Circular/oval, no calcifications||92||85|
|Casting type calcifications||67||47|
|Stellate, no calcifications||98||97|
|Circular/oval, no calcifications||96||95|
|Casting type calcifications||83||77|
|Grade ≥ 2|
|Stellate, no calcifications||95||83|
|Circular/oval, no calcifications||91||70|
Table 9 shows that, among women who had 1–9-mm tumors without casting calcifications, the predictive value of histologic grade and lymph node status for survival simply was not present; and, among women who had in 10–14-mm tumors, the predictive value for long-term survival still was considerably smaller than the predictive value of the presence of casting-type calcifications. The survival of women with 10–14-mm tumors was only noticeably poorer than the survival of women with 1–9-mm tumors when casting calcifications also were present or when the tumor was Grade ≥ 2. Overall, in tumors that measured 1–14 mm, mammographic features were the clearest predictor of survival followed by histologic grade, tumor size, and lymph node status.
In this study, we assessed the role of mammographic features of breast carcinoma as an independent predictor of long-term outcome among women with 1–14-mm invasive breast carcinomas, adjusting for tumor attributes and treatment modality. To the best of our knowledge, the current study has been the largest to date addressing the association between mammographic features of these small breast carcinomas and their histologic tumor characteristics. We found that the mammographic tumor features can serve successfully as independent predictors for long-term outcome. On one hand, there was a single mammographic category of tumors, those associated with casting-type calcifications, which carried an unexpectedly poor long-term prognosis that was not found with any other risk factor in this size range. Conversely, women who had tumors with other mammographic features were found to have excellent 24-year survival, independent of lymph node status or histologic grade in the 1–9-mm size category. These observations strongly suggest the need to take the mammographic features of 1–14-mm, small breast carcinomas into account when planning patient treatment.
All women with 1–9-mm tumors, except for the small group associated with casting-type calcifications, appear to have an excellent 24-year survival without extensive surgery or any adjuvant treatment. In women with 10–14-mm tumors, the treatment consideration for tumors without associated casting-type calcifications should take the lymph node status and histologic grade into account. With regard to the treatment of women with 1–14-mm invasive tumors associated with casting-type calcifications, the results of the current study demonstrated poor survival irrespective of the therapeutic regimens that had been chosen. Further clarification of the effect of the various therapeutic regimens on this special group could be obtained from adjuvant therapy trials by retrospective analysis of the available mammograms. Another approach would be to design and perform a prospective, multicenter trial comparing various adjuvant therapeutic regimens.
The poorer prognosis for women who had tumors with casting-type calcifications was consistent with most of the published literature on the subject,1–4 including correlations observed between a poorer prognosis associated with worse histologic grade5 (including high-grade DCIS).9, 10 Casting calcifications also have been associated strongly with the risk of local recurrence.11
The long-term survival rates among women with 1–9-mm and 10–14-mm invasive breast carcinomas were 72.0% and 52.0%, respectively, when associated with casting-type calcifications that represented high-grade DCIS. These poor survival rates are similar to the rates reported among women with 30–49-mm, Grade 2, lymph node-negative, invasive ductal carcinomas; 20–29-mm, lymph node-positive, Grade 2, invasive ductal carcinoma; 20–29-mm, lymph node-negative, Grade 3, invasive ductal carcinoma; and 15–19-mm, lymph node-positive, Grade 3, invasive ductal carcinoma.1 Conversely, the long-term survival rates among women with 1–9-mm and 10–14-mm invasive breast carcinomas without associated casting-type calcifications were found to be 95.0% and 91.0%, respectively. The basic morphologic difference between these two groups (which may explain the astounding difference in long-term outcome) is the presence of extensive, high-grade DCIS. Study of large-section, submacroscopic histologic images of these tumors demonstrates an unexpectedly large number of oddly shaped, carcinoma-filled ducts in a highly contorted arrangement (Fig. 6).
Tenascin (tenascin-C) overexpression is detectable around these ducts by using immunohistochemical stains, indicating an epithelial-stromal interaction similar to what occurs during the development of the duct system. In the current study, tenascin-C overexpression occurred periductally in all patients with Grade 3 DCIS, although the intensity varied. In the study by Jahkola et al., the corresponding prevalence of this overexpression was 87%.12 We propose that this process of neoductgenesis represents a special type of neoplasia that generates a large volume of neoplastic tissue, as observed directly on large-section histology images and indirectly by the presence of extensive casting-type calcifications on mammograms. It appears that vascular intrusion may occur during the process of neoductgenesis, leading to the histologically demonstrable, extensive lymphatic and/or hematogenous spread. This morphologically in situ neoplastic process actually may behave as an invasive breast carcinoma with a large tumor burden, which likely accounts for the observed high fatality rates in patients with these tumors.
The findings discussed earlier suggest that tumors with a size that normally would categorize them as T1a or T1b, but that are accompanied by casting-type calcifications, actually are not homogeneous with the general population of tumors of this size. The greater tumor burden, as evidenced by their clinical behavior, strongly suggests that they belong in a separate, more advanced-stage category. Inasmuch as staging categories imply an inherent similarity for the purposes of estimating prognosis and guiding therapy, the findings of the current study suggest the need to rethink tumor classification as well as therapy for women with breast carcinomas that have these mammographic appearances.
We also found that the distribution of mammographic features of breast carcinoma varied with age. The same proportions of stellate lesions without calcifications were observed in both age groups. There was a greater proportion of circular/oval-shaped tumors without associated calcifications in women age > 50 years, whereas tumors associated with casting-type calcifications appeared to occur more frequently in women age < 50 years. This finding is consistent with the previous results, which indicated that younger age was related to a poor prognosis among women with T1a and T1b tumors.13 The question arises whether tumors with casting-type calcifications are associated with genetic markers, such as the BRCA1 genotype, HER-2/neu overexpression, and the absence of hormone receptor.
The results of the current study indicate that mammographic features of breast carcinoma are predictive of a long-term risk of breast carcinoma death independently among women with 1–14-mm invasive breast carcinomas. The mammographic features of tumors measuring 1–14 mm are more predictive of long-term survival than tumor size, lymph node status, or histologic grade. The vast majority of patients with 1–14-mm tumors do not have associated casting-type calcifications and have excellent long-term outcomes. However, patients with small invasive tumors associated with casting-type calcifications appear to have a poor prognosis. Therefore, there is an urgent need to develop effective treatment protocols for this particular subgroup.
When we originally described our observations regarding the prognostic value of mammographic features in predicting patient outcomes, we concluded that our findings were preliminary but nonetheless thought provoking with respect to the current inability to identify which women diagnosed with small breast carcinomas truly needed adjuvant therapy.1 We strongly encouraged others to examine their material to determine whether our findings were reproducible, and we also encouraged the initiation of prospective therapy trials. Four years later, as outlined above, our findings have been confirmed by three other investigations and by our own extended material.2–4 The longer term follow-up provides additional confirmation of the reliability of the mammographic signs to predict prognosis. In our judgment, the 99% 24-year survival rate among women with 1–9 mm stellate lesions, the most frequently occurring lesion, provides compelling evidence that there is little potential for adjuvant therapy or radical surgery to improve further on this excellent survival. Insofar as ≥ 55% of screen-detected invasive breast carcinomas are in the 1–14 mm size range, we hope our findings will stimulate further research and discussion among leaders in breast care.
The authors thank Peter Dean, Peter Sasieni, and Jack Cuzick for their helpful discussion and Ms. Inger Hermansson and Ms. Sara Hermansson for administrative assistance.